| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| 体外研究 (In Vitro) |
N-双(2-羟丙基)亚硝胺是一种可能致癌的化学物质[1]。
|
|---|---|
| 体内研究 (In Vivo) |
在 100 ppm 浓度下，暴露于 N-双（2-羟丙基）亚硝胺的大鼠的甲状腺、肝脏和肺部出现了肿瘤。除了 500 ppm 的食道、肾和膀胱之外，两种剂量的大鼠的肺、肝、甲状腺、食道、肾和膀胱均出现肿瘤 [1]。当大鼠受到 N-双（2-羟丙基）亚硝胺（DHPN；2800 mg/kg）刺激时，双酚 A (BPA) 会增加患甲状腺癌的易感性[2]。
- 在雄性和雌性大鼠中，口服N-双(2-羟丙基)亚硝胺（N-Bis(2-hydroxypropyl)nitrosamine，DHPN）表现出剂量依赖性致癌活性。饮水中小鼠剂量为100 ppm、300 ppm和600 ppm时，可诱导多器官肿瘤：300 ppm和600 ppm剂量组大鼠肝细胞癌发生率为80%-100%，600 ppm剂量组雄性大鼠肾细胞癌发生率为40%-60%，300 ppm和600 ppm剂量组大鼠肺腺瘤发生率为20%-30%。随着剂量增加，肿瘤潜伏期缩短（如600 ppm剂量组肝肿瘤潜伏期约24周，而100 ppm剂量组约32周）[1] - 在F344大鼠中，N-双(2-羟丙基)亚硝胺（DHPN）联合过量碘（饮水中）可诱导甲状腺癌：先给予DHPN（饮水中2000 ppm，持续2周），再给予过量碘（饮水中1000 ppm，持续40周）的大鼠，甲状腺滤泡癌发生率为45%-55%。低剂量双酚A（BPA，饮水中0.1 ppm）与DHPN、过量碘联合给药时，可将甲状腺滤泡癌发生率提升至75%-85%，并促进肿瘤进展（肿瘤体积增大、侵袭性增强）[2] |
| 动物实验 |
- For dose-dependent carcinogenicity study: Male and female rats were divided into 4 groups (control, 100 ppm DHPN, 300 ppm DHPN, 600 ppm DHPN) with 20 rats per group. N-Bis(2-hydroxypropyl)nitrosamine was dissolved in drinking water and administered ad libitum for 52 weeks. After the treatment period, rats were observed for an additional 24 weeks. Body weight was measured monthly; at the end of the experiment, rats were euthanized, and major organs (liver, kidney, lung, thyroid) were dissected for pathological examination (hematoxylin-eosin staining) to count tumor number and determine tumor type [1]
- For thyroid carcinoma susceptibility study: Male F344 rats (4 weeks old) were divided into 3 groups (n=15 per group): Group 1 (control): normal drinking water; Group 2 (DHPN+I): N-Bis(2-hydroxypropyl)nitrosamine (2000 ppm in drinking water) for 2 weeks, followed by excess iodine (1000 ppm in drinking water) for 40 weeks; Group 3 (DHPN+I+BPA): DHPN (2000 ppm, 2 weeks) + excess iodine (1000 ppm, 40 weeks) + bisphenol A (0.1 ppm in drinking water, 42 weeks total). Rats were weighed weekly; at week 42, all rats were euthanized, and thyroid glands were removed, fixed in formalin, embedded in paraffin, sectioned, and stained with hematoxylin-eosin for pathological diagnosis (tumor type, incidence, size) [2] |
| 毒性/毒理 (Toxicokinetics/TK) |
N-bis(2-hydroxypropyl)nitrosamine exhibits dose-dependent carcinogenicity in rats: the incidence of liver, kidney, and lung tumors increases significantly with increasing dose (100–600 ppm) [1]
- N-bis(2-hydroxypropyl)nitrosamine (2000 ppm) combined with excess iodine induces thyroid cancer in F344 rats (the incidence of follicular thyroid carcinoma is approximately 50%), and low doses of bisphenol A enhance this carcinogenic effect (increasing the incidence to approximately 80%) [2] |
| 参考文献 |
|
| 其他信息 |
N,N-bis(2-hydroxypropyl)nitrosamine is a nitrosamine with the structure dipropylamine, in which the hydrogen atom bonded to the nitrogen atom is replaced by a nitroso group. It is a genotoxic carcinogen that primarily damages the lungs, liver, thyroid, and kidneys. It is a carcinogen. It is a nitrosamine, secondary alcohol, and diol.
- N-bis(2-hydroxypropyl)nitrosamine (DHPN) is a well-known chemical carcinogen and is often used in animal models to induce multi-organ tumors (liver, kidney, lung, thyroid) for cancer research [1] - The carcinogenic mechanism of N-bis(2-hydroxypropyl)nitrosamine involves metabolic activation in the liver and target organs, leading to DNA alkylation and mutation, thereby driving tumor development and progression [1] - In thyroid cancer models, N-bis(2-hydroxypropyl)nitrosamine initiates thyroid cell transformation, while excess iodine promotes thyroid cell proliferation (a promoting factor), and low-dose bisphenol A enhances this promoting effect by interfering with thyroid hormone signaling [2] |
| 分子式 |
C6H14N2O3
|
|---|---|
| 分子量 |
162.18696
|
| 精确质量 |
162.1
|
| CAS号 |
53609-64-6
|
| PubChem CID |
40828
|
| 外观&性状 |
Colorless to light yellow liquid（Density：1.2266 g/cm3）
|
| 密度 |
1.2±0.1 g/cm3
|
| 沸点 |
352.4±27.0 °C at 760 mmHg
|
| 闪点 |
166.9±23.7 °C
|
| 蒸汽压 |
0.0±1.8 mmHg at 25°C
|
| 折射率 |
1.497
|
| LogP |
-1.2
|
| tPSA |
73.13
|
| 氢键供体(HBD)数目 |
2
|
| 氢键受体(HBA)数目 |
5
|
| 可旋转键数目(RBC) |
4
|
| 重原子数目 |
11
|
| 分子复杂度/Complexity |
110
|
| 定义原子立体中心数目 |
0
|
| SMILES |
O=NN(CC(O)C)CC(O)C
|
| InChi Key |
MNIGYIKCFSPQRJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H14N2O3/c1-5(9)3-8(7-11)4-6(2)10/h5-6,9-10H,3-4H2,1-2H3
|
| 化学名 |
N,N-bis(2-hydroxypropyl)nitrous amide
|
| HS Tariff Code |
2934.99.9001
|
| 存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| 运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| 溶解度 (体外实验) |
DMSO : ≥ 125 mg/mL (~770.70 mM)
|
|---|---|
| 溶解度 (体内实验) |
注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。
注射用配方
注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)(IP/IV/IM/SC等) *生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。 注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil) 示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。 View More
注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)] 口服配方
口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠) 口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素) 示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。 View More
口服配方 3: 溶解于 PEG400 (聚乙二醇400) 请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
| 制备储备液 | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.1656 mL | 30.8280 mL | 61.6561 mL | |
| 5 mM | 1.2331 mL | 6.1656 mL | 12.3312 mL | |
| 10 mM | 0.6166 mL | 3.0828 mL | 6.1656 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;
3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;
4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。
计算结果:
工作液浓度： mg/mL；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH2O，混匀澄清。
(1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。
InvivoChem的所有产品仅用于作科学研究，不面向患者销售
Copyright 2020 InvivoChem LLC | All Rights Reserved 粤ICP备20063088号-1
粤公网安备 44011102003439号
463611831
